Latest News and Press Releases

PharmAla files its final short form prospectus, and announces a signed term sheet with an R&D tax credit financing firm called Radium

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine...

Fungushead has announced its new Angel’s Wing Scholarship, providing a lifetime 25% discount for verified U.S. military vets

PharmAla launches new web portal for MDMA prescribers and appoints a new COO

PharmAla completes first domestic US shipment of MDMA from its new domestic distribution center, and issues shares as debt payment.

TORONTO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and...

TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and...

MAPS names Betty Aldworth and Ismail Lourido Ali as Co-Executive Directors, bringing decades of drug policy expertise.

PharmAla announces completion of onboarding for its US distribution centre and resignation of its Chief Operating Officer.

Psycan discloses troubling statistics showing that Health Canada has begun to deny numerous doctor requests for MDMA and Psilocybin